Amylin starts long-acting AC2993 Phase II

AMLN started a 100-patient double-blind, placebo-controlled U.S. Phase II study of AC2993 LAR, a long-acting release formulation of synthetic exendin-4 to treat Type II diabetes. The trial will measure safety, tolerability, pharmacokinetics and the effects of AC2993 LAR on fructosamine, HbA1c and fasting and post-meal glucose levels. ...